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Patent ductus arteriosus (PDA) is a common diagnosis among
extremely premature infants, especially in those with lung
disease. Treatments are often used to close the PDA. Despite
nearly three decades of research, the question of whether the
benefits of treatments to prevent ductal patency or promote
closure outweigh the risks of these treatments remains
unanswered. The authors rarely use treatments designed to
close the PDA. This article reviews three considerations in
support of this restrained approach: rates of spontaneous
closure of the ductus arteriosus; adverse effect of persistent
ductal patency; and benefits and risks of treatments for closure.
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T
he ductus arteriosus usually closes after a brief
period of right-to-left and bidirectional shunting
following the birth of a healthy term infant. In
contrast, in preterm infants, particularly those with
lung disease, there is a tendency for the ductus
arteriosus to remain patent. Hence, ‘‘patent ductus
arteriosus’’ (PDA) is a common diagnosis in these
infants. Approximately 65% of infants born at less
than 28 weeks’ gestation will have persistent
patency of the ductus arteriosus and will be assigned
the diagnosis of PDA at some time during the early
neonatal period.1 PDA is associated with neonatal
morbidities such as chronic lung disease (CLD)2 3
and necrotising enterocolitis (NEC).4 Although a
cause and effect relationship between PDA and these
morbidities has not been established, many neona-
tologists administer cyclo-oxygenase (COX) inhibi-
tors (eg, indomethacin or ibuprofen) to promote
closure of the ductus arteriosus under the assump-
tion that early closure decreases the likelihood of
these and other morbidities.5 In the USA, COX
inhibitors are given to more than 10 000 premature
infants annually (R H Clark, personal communica-
tion, 2006). A smaller number of infants with a
diagnosis of PDA undergo surgical ligation, most
commonly when medical treatment fails. However,
despite nearly three decades of research, we believe
that the question of whether these treatments
improve outcome remains unanswered. In our
practice, we rarely administer medical treatment
for a PDA and virtually never recommend surgical
closure. This restrained approach to the treatment of
PDA is based on three considerations:
N rates of spontaneous closure of the ductus
arteriosus;
N adverse effect of persistent ductal patency;
N benefits and risks of treatments for closure.
We review each of these considerations below.
RATES OF SPONTANEOUS CLOSURE OF
THE DUCTUS ARTERIOSUS
Nearly all medical treatments are associated with
some risk. Patients with conditions that improve or
resolve without treatment should not be exposed
to even minor risks associated with treatments.
Therefore, treatment to promote closure of the
ductus arteriosus should be considered only in
infants in whom early spontaneous closure will
probably not occur.
Although the ductus arteriosus closes sponta-
neously in nearly all term infants by 3 days of age,6
the natural history of the ductus arteriosus in
preterm infants, particularly extremely premature
infants with lung disease, is unknown because it is
so often perturbed by medical treatments. The best
estimates of rates of spontaneous closure can be
derived from observations of control infants in
placebo-controlled trials of timing of treatments to
close the ductus arteriosus. From these studies,
inferences about the rates of spontaneous closure
can be drawn from observations made before the
age at which treatment for the PDA is prescribed
by the study, or occurs outside the confines of the
study. Using this approach, Van Overmeire et al
provided an estimate of the rate of spontaneous
closure of the ductus arteriosus in moderately
premature infants during the first week of life.7
They investigated the efficacy of early (3 days of
age) compared with late (7 days of age) treatment
for PDA in 380 infants of gestational age 26–
31 weeks who required ventilatory support (con-
stant positive airway pressure or mechanical
ventilation) and a fraction of inspired oxygen
greater than 0.30. At 3 days of age, 67% of infants
either had no PDA or had a small haemodynami-
cally unimportant ductal shunt. One half of the
remaining infants, who all had moderate to severe
shunts, were randomised to receive treatment at
7 days of age if ductal patency persisted.
Spontaneous closure occurred in 44% of these
infants. Therefore, from these data, a rate of
spontaneous closure in excess of 80% by 7 days
of age can be predicted among moderately
premature infants with lung disease.
Although the rate of spontaneous closure for all
premature infants is high, there is a direct
relationship between gestational age and closure.
During the first three to four days of life, the rate
of spontaneous closure is approximately 31%
Abbreviations: BPD, bronchopulmonary dysplasia; CLD,
chronic lung disease; COX, cyclo-oxygenase; IVH,
intraventricular haemorrhage; NEC, necrotising
enterocolitis; PDA, patent ductus arteriosus
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among infants born at 26 and 27 weeks’ gestation, but it is
approximately 21% at 24 and 25 weeks’ gestation.8 This
relationship was observed by Koch et al who estimated that
for each week of increase in gestational age above 23 weeks, the
odds of spontaneous closure increased by a ratio of 1.5.9 In this
study, other factors that predicted closure were antenatal
steroids and the absence of major lung disease. Nemerofsky et al
reported that spontaneous ductal closure at 2 weeks of age
occurred in 50% of ventilated compared with 80% of non-
ventilated very low birthweight infants.10 Of interest in both of
these studies was the observation that spontaneous closure
occurred in a number of infants after the first week of life.
Collectively, these observations regarding the rates of
spontaneous closure narrow the population in whom early
treatment (ie, in the first week of life) would logically be
contemplated. Given the high rate of spontaneous closure
among most premature infants, consideration of early treat-
ment should be limited to extremely premature infants, in
particular, those on respiratory support.
ADVERSE EFFECT OF PERSISTENT DUCTAL PATENCY
Decisions regarding treatment should be made with the aim of
preventing an adverse outcome resulting from persistent
patency, and the outcome should have sufficient impact on
long-term health to justify treatment. These decisions should be
based on reasonable certainty of a cause and effect relationship
between ductal patency and a specific adverse outcome, not
merely association, and treatments should be reserved for
infants at sufficient risk for the outcome. Among the relatively
large percentage of extremely premature infants and the
smaller percentage of more mature infants with PDA, an
important determinant of the decision to treat a PDA is whether
persistent patency is associated with serious morbidities. The
morbidities that have attracted the most attention are CLD and
NEC because they occur with relatively high frequency and may
be associated with serious consequences later in childhood.
Pulmonary physiology and CLD
Large left-to-right ductal shunts may have an effect on
pulmonary function, most notably the mechanical properties
of the lung. Some investigators have reported a decrease in
dynamic lung compliance in the presence of ductal shunt-
ing,11 12 although these changes have not been observed by
others.13 14 Left-to-right shunting does not impair oxygenation,
except perhaps when associated with severe left ventricular
failure. However, a decrease in lung compliance as a result of
shunting may provoke the need to initiate or increase
ventilatory support to maintain adequate ventilation. The
possibility of this cascade of events has led to the hypothesis
that PDA increases the likelihood of respiratory morbidities,
including CLD or bronchopulmonary dysplasia (BPD), by
increasing exposure to mechanical ventilation, an established
risk factor for CLD.15 This hypothesis is supported by a strong
association between the presence of PDA and CLD. For
example, in a population-based study of 1460 infants, PDA
emerged as a risk factor for CLD with an odds ratio of 1.9 after
adjustment for a variety of risk factors (eg, gestational age, sex,
etc.).2 In a more recent study, Oh et al showed a similar
relationship, although of smaller magnitude (odds ratio 1.4),
between PDA and death or BPD.16
Organ blood flow and NEC
A number of authors have hypothesised a ‘‘steal syndrome’’, in
which a large ductal shunt results in decreased diastolic blood
flow to the intestines and tissue ischaemia,17 theoretically
increasing the likelihood of NEC. Based on ultrasonic measure-
ments, premature infants with PDA have decreased splanchnic
and renal blood flow and blood flow velocity compared with
infants without PDA.18 These values increase to levels observed
in infants without PDA following ductal closure. Whether the
decrements in flow result in pathology is uncertain, but
epidemiologic data are suggestive. Dollberg et al explored the
relationship between the presence of a PDA and NEC among
6146 infants born at gestational age 24–34 weeks, whose
outcomes were entered into the Israeli national database.4
The odds ratio for the risk of NEC after adjustment for other
risk factors was 1.85.
Collectively, these studies confirm an association between
PDA and serious neonatal morbidities, and suggest a plausible
explanation for this relationship. However, even with the
knowledge that ductal shunting may perturb organ blood flow
in a manner that may potentiate pathology, these associations
do not prove a cause and effect relationship. It is possible that
PDA is simply one manifestation of a ‘‘sick neonate’’ at greater
likelihood of developing a number of outcomes of severe illness.
Consequences of long-term ductal patency
Little is known about persistent patency of the ductus
arteriosus beyond early infancy, but there is some reason for
concern. Exposure of the pulmonary vasculature to increased
flow from large left-to-right shunts is associated with pulmon-
ary hypertension in the fourth decade of life.19 Even modest
shunts—for example, those resulting from a patent foramen
ovale—increase the risk of pulmonary hypertension if they
persist into adulthood.20 It is not clear whether similar
pathology results from persistent ductal patency. This is
because the small calibre of the PDA may result in a
diminishing shunt fraction with advancing age as total cardiac
output increases. However, it is possible that exposure of the
pulmonary vasculature to large shunts during a critical period
of development may result in abnormal growth of the
pulmonary vasculature and long-term consequences. An addi-
tional risk may be the increased likelihood of endoarteritis.21
BENEFITS AND RISKS OF TREATMENTS FOR CLOSURE
As with all medical therapies, treatment to promote closure of
the ductus arteriosus should be made with knowledge of the
risks and benefits of the treatment. Clinical trials of treatments
whose goal is closure of the ductus arteriosus should quantify
these benefits and risks. In addition, they have the potential to
provide insights about the contribution of the PDA to
morbidity. If the PDA is related to morbidity in a causal
relationship, closure should result in a reduction in the
incidence of the morbidity. In this section, we examine the
benefits of medical treatment and surgical ligation in relation to
reduction in morbidities associated with PDA.
COX inhibitors: indomethacin and ibuprofen
The use of the COX inhibitor, indomethacin, to promote closure
of the ductus arteriosus was first reported over three decades
ago.22 Since then, the efficacy of this drug, as well as another
COX inhibitor, ibuprofen, has been investigated extensively.
Three strategies of treatment have been described:
(1) prophylactic treatment of infants at risk for persistent
ductal patency, usually initiated during the first day of life;
(2) treatment of infants with PDA accompanied by signs and
symptoms consistent with a major ductal shunt;
(3) treatment of infants who have echocardiographic evidence
of PDA but lack these signs and symptoms.
The Cochrane Database of Systematic Reviews includes reviews of
two of these strategies of therapy.23 24 The review of prophylactic
indomethacin for preventing mortality and morbidity in
preterm infants suggests that there are several short-term
benefits of this treatment, including a reduction in the
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incidence of symptomatic PDA and serious intraventricular
haemorrhage (IVH) (fig 1). In addition, fewer surgical ligations
of the PDA are performed following this treatment. However,
despite improvements in these outcomes, mortality and other
morbidities (eg, CLD and NEC) are not reduced, and the
reduction in severe IVH does not translate into improved
developmental outcome.25 Treatment with indomethacin of
infants with asymptomatic PDA seems to result in a similar
profile of benefits with one notable exception24 (fig 2). Use of
indomethacin in this strategy does not reduce the likelihood of
IVH. This finding is not surprising because the treatment usually
begins after the postnatal age at which IVH most probably will
occur. There have been no reports of large, controlled trials of
indomethacin for the treatment of symptomatic PDA conducted
in the post-surfactant era. A comprehensive report of older trials
suggests a similar profile of risks and lack of long-term benefits
using this strategy.26 Treatment with indomethacin results in
closure of approximately two-thirds of symptomatic PDAs but
does not reduce mortality or a serious morbidity.
There has been considerable recent interest in ibuprofen as
an alternative to indomethacin because it seems to have less
effect on renal and cerebral blood flow. This potential
advantage does translate into fewer infants with impaired
renal function during treatment with ibuprofen compared with
indomethacin.28 Ibuprofen seems to be as effective at promoting
ductal closure, but like indomethacin, does not appear to
reduce mortality or any serious morbidity; it may increase the
likelihood of CLD when compared with indomethacin.
Although a non-significant reduction in serious IVH was
observed in a recent study of prophylactic ibuprofen,29 this
finding was not observed in the Cochrane review that included
the results of four trials.30
Although no demonstrable benefit seems to result from
closure of the PDA, one might still conclude that treatments to
promote closure are indicated for the singular benefit of
elimination of the ductus arteriosus if these therapies were
entirely benign. Unfortunately, COX inhibitors do have adverse
effects, and some of these may have long-term consequences.
They have potent effects on vasculature and organ perfusion.31
Decreased urine output and raised creatinine levels are frequent
occurrences during treatment with indomethacin and ibupro-
fen, although this adverse effect seems to be less common with
ibuprofen and is reversible with both drugs. Recent data
indicate that indomethacin, especially in conjunction with
corticosteroids, may cause intestinal perforation.32 33 A potential
adverse effect was suggested from results of the largest trial to
date of the effects of the prophylactic use of indomethacin.25
Infants without persistent ductal patency who were exposed to
indomethacin were at increased likelihood of developing BPD
compared with infants without PDA not exposed to the drug.34
Although this phenomenon may occur as a result of fluid
retention during indomethacin treatment, and its negative
effect on lung function, an alternative explanation is that
indomethacin has a direct toxic effect on the lung.
Surgical closure of the ductus arteriosus
Surgical closure of the ductus arteriosus is usually reserved for
infants in whom medical treatment has failed. Infants who
Figure 1 A comparison of selected outcomes generated by the Cochrane Database of Systematic Reviews meta-analysis of randomised controlled trials of
prophylactic intravenous indomethacin for the prevention of mortality and morbidity in preterm infants with a patent ductus arteriosus (PDA). The point
estimates with 95% confidence intervals are generated by combining the data from each trial, and the number of infants with the outcome of interest in each
group is in the numerator with the total number of infants in the denominator.27 IVH, intraventricular haemorrhage. (Adapted from Laughon et al with
permission from Lippincott Williams & Wilkins.)
Figure 2 A comparison of selected outcomes generated by the Cochrane Database of Systematic Reviews meta-analysis of randomised controlled trials of
indomethacin for asymptomatic patent ductus arteriosus (PDA) in preterm infants. The point estimates with 95% confidence intervals are generated by
combining the data from each trial, and the number of infants with the outcome of interest in each group is in the numerator with the total number of infants
in the denominator.27 IVH, intraventricular haemorrhage. (Adapted from Laughon et al with permission from Lippincott Williams & Wilkins.)
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undergo ligation are often critically ill. Therefore, it is not
surprising that outcome following surgery is poor.35 In addition
to high morbidity and mortality inherent to the population,
there are complications related to the procedure, such as
recurrent laryngeal nerve damage and pneumothorax. Recent
reports suggest that there is a period of left ventricular
dysfunction immediately following ligation,36 and that infants
whose ductus arteriosus is ligated are at greater risk for poor
developmental outcome compared with infants treated medi-
cally.37 Unfortunately, there have been no recent controlled
trials comparing outcomes following ligation with outcomes
following either placebo or medical treatment. Therefore, the
risks and benefits of surgical ligation of the PDA are unknown.
It is discouraging that after the conduct of numerous trials of
therapies for closure of the ductus arteriosus over several
decades, we have little knowledge about their benefits and
risks. This lack of knowledge has resulted, in part, from
limitations imposed by study designs. Under the assumption
that closure of a PDA is beneficial, almost all clinical trials in
the modern era have focused on the most expeditious way in
which to close a PDA. None have looked at the more
fundamental question of whether closing the PDA improves
outcome. Those trials that have included control groups treated
with a placebo have permitted treatment of PDA that persisted
after reaching a defined study endpoint, often just days after
enrolment. This study design has resulted in high rates of
treatment in the ‘‘placebo’’ group (usually in the range of 40%)
and has markedly handicapped our ability to answer the
fundamental question of whether closure of the PDA influences
outcome. In addition, our ability to detect adverse effects of
treatment is equally compromised. Despite these handicaps, the
message from clinical trials is not encouraging. There is no
evidence that the use of medical treatments for the prevention
and treatment of PDA decreases mortality or serious morbidity,
despite success in closure of the PDA.25 26 29 38 39
COMMENTARY
Treatments to promote closure of the PDA cannot be justified
on the basis of proven benefit, unless one finds the reduction in
severe IVH with the prophylactic administration of indometha-
cin a sufficiently compelling benefit to justify its use. Therefore,
the debate regarding the use of these therapies is in reality
philosophical in nature. How should treatment decisions be
made for individual infants in the absence of knowledge about
benefits and risks of a treatment? Some would argue that
biological plausibility of these treatments and the association
between patency of the ductus arteriosus and morbidity is
sufficient support for treatment. However, many commonly
accepted therapies, whose use was supported by plausibility
and an improvement in short-term surrogate outcomes, were
ultimately proved to be ineffective, hazardous and occasionally
catastrophic.40
We argue that the converse approach should be undertaken.
Therapies to prevent patency or effect closure of the ductus
arteriosus should not be used unless there is irrefutable
evidence of harm resulting from a PDA. Qualifying circum-
stances might include intractable hypotension or refractory
congestive heart failure attributable to large aortopulmonary
ductal shunts. Further, we urge the medical community to
conduct trials that will provide clinicians with a precise
understanding of the benefits and risks of treatments designed
to close the ductus arteriosus. These trials would of course be
randomised and placebo controlled. Besides evaluation of
mortality and morbidity during the initial hospitalisation,
outcomes of particular interest are: cardiopulmonary function
in infants with persistent patency beyond the neonatal period;
and adverse events associated with medications and procedures
that may be required for treatment or closure of the PDA later
in infancy or childhood. Some might argue that such trials
would be unethical given the widespread acceptance and use of
these treatments. We argue the contrary—that is, the medical
community has an ethical obligation to conduct such trials
rather than continue to use treatments with uncertain benefits
and risks.
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